Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026?

CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than 30%. Overall, the stock has declined more than 60% of the past five years. It hasn't been a good stock to own, especially when compared to the S&P 500, which has risen by 85% over that stretch.The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has remained fairly underwhelming. But its development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), is optimistic that 2026 will be a better year.There are still many question marks around CRISPR's stock today. And with a market cap of around $5.4 billion, it's a modestly valued healthcare company with potential upside, but also some risk. What should you do with it, heading into 2026: buy, sell, or hold?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool